|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, PAR2 deficiency reshaped the tumor microenvironment through accumulation of tumor-promoting myeloid cells including tumor-associated macrophages and myeloid-derived suppressor cells (MDSCs) and reduction of anti-tumor T cells, which established an immunosuppressive microenvironment and facilitated tumor progression.
|
31733286 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR2 mediated tryptase-induced cell migration and might contribute to the invasion of cancer cells at the edge of tumor.
|
31598400 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TF is the receptor and scaffold of coagulation proteases cleaving protease-activated receptor 2 (PAR2) that plays pivotal roles in angiogenesis and tumor development.
|
29246902 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Knockdown of PAR2 also inhibited hepatocellular carcinoma tumor cell growth and liver metastasis in nude mice.
|
29563756 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Confocal microscopy of PAR2-driven mammary gland tumors in vivo, as well as in vitro confirms the association between PAR2 and LRP6.
|
28418856 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also provide molecular evidence that protease-activated receptor 2 activation followed by PI3K-AKT activation and GSK3β inactivation is involved in these processes and that β-catenin, a well known tumor-regulatory protein, contributes to this signaling pathway.
|
28522609 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therapeutically targeting PAR2 may thus be a promising approach in preventing TGF-β-dependent driven metastatic dissemination in PDAC and possibly other stroma-rich tumour types.
|
27248167 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The impact of LX-2-expressed PAR2 on tumour growth in vivo was monitored using HCC xenotransplantation experiments in SCID mice, in which HCC-like tumours were induced by coinjection of LX-2 cells and Hep3B cells.
|
27473374 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protease-activated Receptor-2 (PAR-2)-mediated Nf-κB Activation Suppresses Inflammation-associated Tumor Suppressor MicroRNAs in Oral Squamous Cell Carcinoma.
|
26839311 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This protease, acting on PAR-2 by its proteolytic activity, has angiogenic activity stimulating both human vascular endothelial and tumor cell proliferation in paracrine manner, helping tumor cell invasion and metastasis.
|
25295247 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical staining and western blotting were performed to determine TF, FVII, PAR2 and light chain 3 (LC3A/B) expressions in tumors and their contiguous normal regions.
|
24853422 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In parallel, when a truncated PAR2 was utilized in a xenograft mouse model, it inhibited PAR1-PAR2-driven tumor growth in vivo.
|
24177339 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intrapleural administration of MPM cells expressing tissue factor and PAR1 but lacking EPCR and PAR2 (F2RL1) generated large tumors in the pleural cavity.
|
23539451 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recent studies have suggested that protease-activated receptor-2 (PAR-2) activity correlates with cell proliferation and tumor growth, and its activation induces expression of cyclooxygenase-2 (COX-2).
|
20740367 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The purpose of this study was to investigate the secretion of tumor-derived trypsin and the expression of its specific receptor, protease-activated receptor-2 (PAR-2), in ICC using cell lines and surgical specimens.
|
20198321 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Angiogenesis in the tumor is related to overall survival of NPC patients (P=0.001), and exhibits strong PAR-2 expression or LMP-1 expression in tumors associated with increased intratumoral microvessel density (P=0.026 and 0.006, respectively).
|
19269113 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PAR-2 siRNAs dramatically suppressed tumor growth in the xenograft model.
|
17935125 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, palpable tumors and multifocal disease developed slower in PAR2(-/-) mice, and as a consequence of delayed tumor onset, metastasis was reduced.
|
18757438 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PAR-2 histoscores and mRNA levels significantly (P < 0.05) increased in 12 of 30 metastatic lymph node lesions from the corresponding primary tumor.
|
18937843 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
All tumors from cervical cancer patients expressed PAR-2 (immunoreactive score was higher in poorly differentiated tumors).
|
17936340 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical staining revealed distribution of PAR-2, dominantly in cancer cells and faintly in stromal cells of the tumor.
|
17761706 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our results provide early experimental evidence for a tumor-protective role of PAR(2).
|
17476297 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR-1 and PAR-2 in the cells forming the tumor microenvironment suggest that these receptors mediate the signaling of secreted thrombin and trypsin in the processes of cellular metastasis.
|
11395381 |
2001 |